Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.

ABSTRACT:

Rationale

The effectiveness and safety of aztreonam lysine for inhalation (AZLI) in patients with cystic fibrosis (CF) on maintenance treatment for Pseudomonas aeruginosa (PA) airway infection was evaluated in this randomized, double-blind, placebo-controlled study.

Objectives

To evaluate the safety and efficacy of inhaled aztreonam lysine in controlling PA infection in patients with CF.

Methods

After randomization and a 28-day course of tobramycin inhalation solution (TIS), patients (n = 211; > or =6 yr; > or =3 TIS courses within previous year; FEV(1) > or = 25% and < or =75% predicted values) were treated with 75 mg AZLI or placebo, twice or three times daily for 28 days, then monitored for 56 days. The primary efficacy endpoint was time to need for additional inha

SUBMITTER: McCoy KS 

PROVIDER: S-EPMC2577727 | biostudies-literature | 2008 Nov

REPOSITORIES: biostudies-literature